A Phase II Study of Tazemetostat in Patients with Recurrent or Persistent Malignant Mesothelioma

Full Title

A Phase 2, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with Relapsed or Refractory Malignant Mesothelioma with BAP1 Loss of Function

Purpose

Tazemetostat is an investigational drug that kills cancer cells by stopping a gene called EZH2 from working. EZH2 is also involved in the function of another gene called BAP1, which may be missing in mesothelioma cells.

In this study, researchers are evaluating the safety and effectiveness of tazemetostat in patients with malignant mesothelioma whose cancer continues to grow or came back despite treatment with pemetrexed. Tazemetostat is taken orally (by mouth).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have malignant mesothelioma whose cancer continues to grow or came back despite treatment with pemetrexed.
  • Patients must recover from the serious side effects of previous treatments before entering the study.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is for patients age 18 and older.

For more information and to inquire about eligibility for this study, please contact Dr. Marjorie Zauderer at 646-888-4656.

Protocol

16-1034

Phase

II

Investigator

Co-Investigators

Diseases